| Stockholder | Stake | Shares bought / sold |
|---|---|---|
| Wellington Management Co. LLP | 2.94% | -233,290 |
| Loomis, Sayles & Co. LP | 2.46% | -127,584 |
| Geode Capital Management LLC | 1.85% | +237,090 |
| Putnam Investment Management LLC | 1.26% | +849 |
Is Regeneron Pharmaceuticals efficiently growing its dividend?
Apr 14, 2022 · Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, P Roy Vagelos, Plew Daniel P Van, and …
Will Regeneron Pharmaceuticals (regn) gain on Checkmate's acquisition?
15 hours ago · JPMorgan Chase & Co. boosted its stake in shares of Regeneron Pharmaceuticals by 11.9% in the 4th quarter. JPMorgan Chase & Co. now owns 4,591,529 shares of the biopharmaceutical company’s stock...
Does REGON Pharmaceuticals stock pay a dividend?
15 hours ago · JPMorgan Chase & Co. increased its position in shares of Regeneron Pharmaceuticals by 11.9% in the fourth quarter. JPMorgan Chase & Co. now owns 4,591,529 shares of the biopharmaceutical company’s...
Where can I buy regn shares?
19 hours ago · The offering price values Checkmate at a total equity value of nearly $250 million, and the company shares have gained ~54% in the pre …
Can I buy stock in Regeneron?
You can purchase stock in our company through a registered brokerage or stock purchase service provider of your choice. You cannot buy Regeneron stock directly from the company.
Is Regeneron a good stock to buy?
Regeneron ( REGN 2.25% ) has been one of the better-performing biotech giants in the past year, with the company's shares rising by 33% in the past 12 months compared to the S&P 500's gains of about 9%.Mar 11, 2022
Why is Regeneron going down?
Regeneron Pharmaceuticals on Friday issued financial results that substantially beat Wall Street expectations. Shares dropped in the premarket hours, however, as the Covid-19 therapeutic that played a large part in the stock's more than 30% climb in 2021 appears to be losing its relevance.Feb 4, 2022
Why is Regeneron stock so high?
Summary. Regeneron has grown at a rapid pace over the past few years, but still has room to grow due to its great management team and strong pipeline. Regeneron trades at very low multiples in regard to its net income and free cash flow, which presents a major opportunity as it continues to grow and expand operations.Feb 22, 2022
Will Regeneron be worth more than Amazon?
To reach Amazon's current market value, Regeneron's market cap would have to increase more than 2,600% over the coming nine years. The potential success of pipeline programs could spur major gains. But it seems unlikely the company's market value would increase more than twice as much as it did over the past decade.Oct 28, 2021
How high will Regeneron go?
The 20 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals Inc have a median target of 696.00, with a high estimate of 843.00 and a low estimate of 565.00.
Why is Regeneron so cheap?
They are a very profitable company with a promising outlook and strong balance sheet. Currently, the market is discounting their value due to the overestimation of threats from biosimilars and the discontinuation of COVID treatment.Oct 4, 2021
Is Regeneron Pharmaceuticals a buy right now?
18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are c...
How has Regeneron Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?
Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the Wo...
When is Regeneron Pharmaceuticals' next earnings date?
Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast f...
How were Regeneron Pharmaceuticals' earnings last quarter?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings data on Friday, February, 4th. The biopharmaceutical company reported $...
What price target have analysts set for REGN?
18 brokers have issued twelve-month price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $575.00 to $850.00. On average,...
Who are Regeneron Pharmaceuticals' key executives?
Regeneron Pharmaceuticals' management team includes the following people: Leonard S. Schleifer , Co-President, Chief Executive Officer & Director...
What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?
423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com . Leonard S. Schleifer has an approval rating of 87%...
Who are some of Regeneron Pharmaceuticals' key competitors?
Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Bi...
What other stocks do shareholders of Regeneron Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NV...
Is Regeneron Pharmaceuticals a buy right now?
What stocks does MarketBeat like better than Regeneron Pharmaceuticals?
17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 13 buy ratings for the stock.
When is Regeneron Pharmaceuticals' next earnings date?
Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regeneron Pharmaceuticals wasn't one of them.
How were Regeneron Pharmaceuticals' earnings last quarter?
Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for Regeneron Pharmaceuticals.
How has Regeneron Pharmaceuticals' stock price been impacted by COVID-19?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported $25.80 earnings per share for the quarter, beating the consensus estimate of $8.81 by $16.99.
How will Regeneron Pharmaceuticals' stock buyback program work?
Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 40.0% and is now trading at $650.49.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for REGN?
Regeneron Pharmaceuticals declared that its board has initiated a stock repurchase program on Tuesday, November 5th 2019, which permits the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy up to 2.9% of its shares through open market purchases.
